Clinical trial NCT00516165: RAD001 in Advanced Hepatocellular Carcinoma
Official title: A Phase I/II Study of RAD001 in Advanced Hepatocellular Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Hepatocellular Carcinoma
Keywords: liver cancer
RAD001
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: Dana-Farber Cancer Institute
name: Beth Israel Deaconess Medical Center
name: Novartis
First posted: 2007-08-15
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Laboratory studies have shown that RAD001 can prevent cells from multiplying. Consequently, the study drug is being tested in medical conditions in which excessive cell multiplication (as in cancer) needs to be stopped. The main purpose of this research study is to find the highest dose of RAD001 that can be given safely (without causing severe side effects) and to learn the effects (good or bad) RAD001 has on participants with liver cancer.

Detailed description: * Participants will be given a supply of the study drug RAD001 to be taken at home. They will be asked to take the study drug every morning on an empty stomach and will be given a study drug diary to record the time/date each time they take RAD001. Each 6 week period of time is called a cycle of study treatment.
* We are looking for the highest dose of RAD001 that can be given safely. Therefore not every participant will receive the same dose of RAD001.
* Participants will come to the clinic every other week. At each of these visits, a physical examination and blood tests will be performed.
* A CT and MRI will be repeated every 6 weeks during the first 3 cycles of treatment then every 12 weeks thereafter.

Eligibility criteria: Inclusion Criteria:

* Unresectable of metastatic HCC. Patients must have prior core biopsy to confirm the diagnosis of HCC and have archived tissues available for correlative studies
* At least one measurable site of disease according to RECIST criteria that has not been previously irradiated. If it has had previous radiation to teh marker lesion(s), there must be evidence of progression since the radiation
* 0-2 prior systemic chemotherapy and biologic regimens for hepatocellular carcinoma
* Patients with prior chemoembolization history can participate in the study if the chemoembolization was performed more than 4 weeks ago and patients must have measurable disease outside of prior chemoembolization field
* 18 years of age or older
* Minimum of 4 weeks since any major surgery or completion of radiation
* Minimum of 4 weeks since completion of all prior systemic anticancer therapy
* ECOG performance status of 0-2
* CLIP score of equal to or less then 3
* Adequate bone marrow, liver and renal function as outlined in the protocol

Exclusion Criteria:

* Prior treatment with any investigational drug within the preceding 4 weeks
* Chronic treatment with systemic steroids or another immunosuppressive agent
* Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
* Patients with any severe and/or uncontrolled medical conditions or other condition that could affect participation in the study
* Known history of HIV seropositivity
* Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001
* Active, bleeding diathesis
* Women who are pregnant or breast feeding
* Patients who have received prior treatment with an mTor inhibitor
* Patients with known hypersensitivity to RAD001 or other rapamycins or its excipients
* History of non-compliance to medical regimens
* Patients with a positive dipstick for urine protein (reading of 2+ or greater) will then undergo a 24-hour urine collection for protein. If patients have a 2g or greater of protein/24hr, they will be excluded from the study.

Primary outcomes:
measure: Maximum Tolerated Dose of RAD001 in Patients With Advanced Hepatocellular Carcinoma (HCC).
timeFrame: 2 years
measure: Progression-free Survival Rate at 24 Weeks
timeFrame: 2 years
Secondary outcomes:
measure: Number of Patients With Adverse Events Who Were Treated With RAD001 for Advanced HCC
timeFrame: 2 years
measure: Overall Response Rate
timeFrame: 2 years
measure: Time to Progression
timeFrame: 2 years
measure: Overall Survival
timeFrame: 2 years
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Boston
country: United States
facility: Dana-Farber Cancer Institute
state: Massachusetts
city: Boston
country: United States
facility: Beth Israel Deaconess Medical Center
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Andrew X. Zhu, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Treiber G. mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther. 2009 Feb;9(2):247-61. doi: 10.1586/14737140.9.2.247.